Autonomix Medical, Inc. (NASDAQ: AMIX) shares surged 116.57% to $11.63 in Monday’s after-hours session after the company announced a $4.9 million warrant inducement agreement. The stock had closed the regular session up 1.90% at $5.37. The agreement covers the immediate cash exercise of July 2026 Warrants for 857,462 common shares at $5.75 each and is expected to generate approximately $4.9 million in gross proceeds before financial advisory fees and estimated offering expenses. In return, Autonomix will issue unregistered Series E-1 and Series E-2 warrants covering an aggregate of 1.07 million shares, with an exercise price of $6.25 per share and a five-year term. The closing is expected on or about Aug. 26, 2026, subject to customary conditions. Autonomix’s investigational catheter-based microchip sensing array is being developed for precision nerve-targeted treatments, initially focused on pancreatic-cancer pain, with potential applications in cardiology, hypertension and chronic pain management. The technology has not been cleared for marketing in the United States. The company had a market capitalization of $5.21 million, a 52-week trading range of $2.44 to $32.55 and a one-year share decline of 74.93%.